NCT04951349View on ClinicalTrials.gov

Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

January 21, 2021

Primary Completion Date

May 30, 2021

Study Completion Date

May 30, 2021

Conditions
Covid19
Interventions
DRUG

GX-03

Same dosage used in Bactroban Nasal studies.

DRUG

Petrolatum ointment

Viscous ointment similar in form to study drug.

Trial Locations (3)

Unknown

Gorgas Memorial Research Hospital, Panama City

Hospital Modular COVID-19, Panama City

Hospital Santo Tomas, Panama City

Sponsors

Lead Sponsor

Turn Therapeutics
All Listed Sponsors
collaborator

Gorgas Memorial Institute for Health Studies

UNKNOWN

collaborator

Hospital Santo Tomas

OTHER

collaborator

Hospital Modular - Covid-19

UNKNOWN

lead

Turn Therapeutics

INDUSTRY

NCT04951349 - Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19. | Biotech Hunter | Biotech Hunter